class 1 integron showed 100% nucleotide sequence identity to the corresponding segment of a plasmid from the human clinical P. aeruginosa strain B3 isolated in Guangzhou (accession no. EU588392). Moreover, the 3 ′ conserved region of the integron (qacED1 and sul1) and the upstream region of the bla IMP-45 gene including aacA4, the 5 ′ conserved segment (intI1) of the integron and a Tn1403-like transposon (tnpR and tnpA) exhibited 99.9% (2348/2349) and 100% (5728/5728) nucleotide sequence identity, respectively, to corresponding regions of plasmid pOZ176 from a clinical P. aeruginosa isolate also found in Guangzhou (Figure 1) .
In companion animals, carbapenemase-producing Escherichia coli carrying bla NDM-1 or bla OXA-48 and K. pneumoniae carrying bla OXA-48 have been isolated from clinical infections. 7, 8 The future will show whether these observations represent 'the tip of the iceberg' or rare accidental findings. 8, 9 In the present case, the frequency of identification of P. aeruginosa ST308 from human clinical samples as well as the high level of similarity of the genetic environment of bla IMP-45 from canine P. aeruginosa with integrons found in human P. aeruginosa strongly suggest a human-to-dog transfer of this IMP-45-producing isolate. Considering that (i) carbapenems are not approved for use in animals and (ii) most of the carbapenemase genes found in animals have been shown to be part of multiresistance integrons or multiresistance gene regions, 3 ,10 -12 co-selection and co-transfer of carbapenemase genes under the selective pressure imposed by other antimicrobial resistance genes seem to play a major role in the dissemination of carbapenemase genes. Moreover, the close contact between humans and their pet and companion animals facilitates the acquisition of carbapenem-resistant isolates of human origin by pet and companion animals. Nevertheless, surveillance of bacteria of animal origin for carbapenemase producers and prudent use of antimicrobial agents to decrease the options for co-selection of carbapenemase genes in animals are urgently warranted.
Sir, Aminoglycosides are very potent bactericidal antimicrobials, but their clinical utility is limited by nephrotoxicity. 1 Although being relevant for all systemic aminoglycosides, nephrotoxic potential appears to differ within the drug class. For example, compared with tobramycin, gentamicin has relatively high tissue accumulation in the renal proximal tubules, explaining its increased nephrotoxic potential. 2 This has been confirmed in animal studies. 3 The results from the only double-blind randomized clinical trial showed that multiple daily dosed (MDD) gentamicin was indeed more nephrotoxic than MDD tobramycin in humans. 4 Over the past two decades, traditional MDD schedules of aminoglycosides have largely been replaced by once-daily dosed (ODD) aminoglycoside regimens with more favourable toxicity profiles. 5 To date, the risk of developing nephrotoxicity in patients treated with ODD gentamicin has never directly been compared with the risk in patients treated with ODD tobramycin. Therefore, we investigated the incidence of the development of nephrotoxicity in patients with suspected or proven infection treated with ODD gentamicin or ODD tobramycin.
In a retrospective cohort study, adult patients with nosocomial infections who were administered systemic gentamicin or tobramycin at a 500 bed teaching hospital between January 2008 and December 2012 were selected from the electronic medication records. In February 2010, the local antibiotic guidelines switched from gentamicin to tobramycin for all indications requiring aminoglycoside treatment, without any changes in the treatment and monitoring protocol. Patients were eligible for inclusion if they were treated with 4 -6 mg/ kg/day of ODD gentamicin or tobramycin for ≥3 days. Aminoglycoside dosing was guided by drug concentration monitoring, targeting peak concentrations of 15 -20 mg/L and trough concentrations ,0.5 mg/L. Drug concentrations were monitored at least twice weekly. Two serum creatinine concentrations were required for inclusion: one drawn within 48 h before therapy and one drawn within a time frame of 48 h after initiation and 48 h after cessation of therapy. Exclusion criteria were a serum creatinine concentration ≥250 nmol/ mL, an estimated glomerular filtration rate [eGFR; calculated with the modification of diet in renal disease (MDRD) formula 6 ] of ≤20 mL/min at baseline, admission to the intensive care unit and a diagnosis of endocarditis. A waiver for consent was provided by the local ethics committee. Nephrotoxicity was identified by the acronym RIFLE (risk, injury, failure, loss of kidney function and end-stage kidney disease), excluding urine production values. 7 The rise in serum creatinine was determined by subtracting the initial concentration from the highest measured concentration drawn between 48 h after initiation and 48 h after cessation of therapy. 4 The incidence of nephrotoxicity between treatment groups was compared by univariate analysis and multivariate logistic regression analyses including predictive determinants, i.e. aminoglycoside, gender, age, weight, ward, pretreatment creatinine and eGFR, cumulative dose and duration of therapy.
Of the 2889 courses that were selected, 382 unique patients met the inclusion criteria and nephrotoxicity was compared in 202 and 180 patients receiving gentamicin or tobramycin, respectively. Similar numbers and percentages of patients were excluded per criterion in each treatment group (data not shown). The baseline characteristics of the included patients did not differ between the groups ( Table 1) .
The incidence of progression to RIFLE stage R was greater in the gentamicin group, with nephrotoxicity developing in 43 of 202 patients (21.3%) compared with 19 of 180 (10.6%) given tobramycin (OR 2.4, 95% CI 1.2 -4.7, P ¼ 0.012). RIFLE stages I and F were more frequently observed in patients on gentamicin, but this difference was not statistically significant due to the small numbers. During multivariate analysis, only gentamicin use (P ¼ 0.008) was retained by the model as an independent predictor of progression to RIFLE stage R. These results did not alter after correction for difference in the baseline eGFR. Mean increases in serum creatinine were 13.3 nmol/mL for gentamicin and 0.1 nmol/mL for tobramycin (P ¼ 0.02). The relative decrease in eGFR between the groups showed a trend of a higher loss of eGFR for patients given gentamicin (4.8% versus 1%, P ¼ 0.07). This large retrospective study shows that ODD gentamicin is more nephrotoxic than ODD tobramycin in infected patients treated with an aminoglycoside for ≥3 days. To our knowledge, this is the first study directly comparing the nephrotoxic potential of these two most frequently used aminoglycosides. Despite the retrospective design with consecutive cohorts, the risks of both selection and time bias appear low since, per criterion, similar numbers of patients were excluded and there were no significant differences between characteristics of both included and eligible patients (data not shown for the latter). The validity of our outcomes is strengthened by the large cohort investigated and the hospital-wide switch to tobramycin in all aminoglycoside indications. Nevertheless, future prospective randomized studies remain warranted to confirm these results. In conclusion, our data suggest that in the once-daily dosing era, a further reduction of the incidence of nephrotoxicity may be obtained by preferring tobramycin over gentamicin as first-line aminoglycoside in infected patients.
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Sir, Sepedonium is an environmental fungus that is not considered to be a cause of human disease. We present, along with a review of the literature, a unique case of a man with localized, recalcitrant, intra-abdominal Sepedonium infection.
A man in his 60s with congestive heart failure, poorly controlled diabetes mellitus type I and end-stage renal disease on peritoneal dialysis presented to our institution with abdominal pain and a cloudy peritoneal dialysate. Peritoneal dialysate analysis revealed 4000 white blood cells/mL with 80% neutrophils and a negative Gram stain. A CT scan of the abdomen and pelvis showed a 6.6×6.8 cm fluid collection near the tip of the peritoneal dialysis catheter. The catheter was removed on hospital Day 5, and on Day 7 a colony of mould grew from catheter tip and peritoneal fluid specimens.
Early growth on fungal medium (Sabouraud Dextrose Agar pH 5.6; Thermo Fischer Scientific, Lenexa, KS, USA) raised a suggestion of Scedosporium spp. and oral voriconazole was initiated. However, the patient developed delirium and visual hallucinations, prompting a change to 5 mg/kg liposomal amphotericin B intravenously daily on hospital Day 11. Upon maturation, the mould was woolly white with a light brown underside (Figure 1a) . Microscopy revealed septated hyphae with spherical, thick-walled conidia consistent with Sepedonium (Figure 1b) . A DNA probe for Histoplasma capsulatum was negative and Sepedonium was confirmed by a reference laboratory.
On hospital Day 13, the right lower quadrant fluid collection was drained percutaneously and a drainage catheter was placed, with cultures again yielding Sepedonium. The percutaneous catheter was removed after 1 week due to a low output. However, 3 days after catheter removal, the patient had recurrent abdominal pain and a repeat CT showed a reaccumulation of fluid measuring 5.7×4.2 cm. Repeat fluid drainage and fungal cultures revealed Sepedonium despite 2 weeks of liposomal amphotericin B treatment.
Since comorbidities precluded surgical debridement, five percutaneous drainage procedures were performed to remove fluid
